Medical education videos
Recognizing and Addressing the Risks of Shifting Epidemiology of Adult Pneumococcal Disease
In this video, we discuss the ongoing burden and the shifting epidemiology of pneumococcal disease in adults and highlight the October 2024 CDC recommendations for adult pneumococcal disease.
A PCV Specifically Designed to Help Protect Against Adult Pneumococcal Disease
In this video, we review the robust clinical program for CAPVAXIVE, Pneumococcal 21-valent Conjugate Vaccine, and highlight the October 2024 CDC recommendations for adult pneumococcal disease.

Learn about CAPVAXIVE, a PCV specifically designed for adults that helps protect against the serotypes responsible for the most cases of adult IPD at a national level1-3,a
Share with health care professionals
aBased on CDC ABC surveillance data from the years 2018–2022, representing ~35 million persons and 10 states across the US. Regional variations may exist.1,3-9
ABC, Active Bacterial Core; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; US, United States.
References:
- Data available on request from Merck National Service Center via email at daprequests@merck.com. Please specify information package US-PVV-00504.
- ABCs bact facts interactive data dashboard. SPN serotypes 1998-2022. Centers for Disease Control and Prevention. Last Updated August 28, 2024. Accessed October 16, 2024. https://www.cdc.gov/abcs/bact-facts/data-dashboard.html
- 1998-2022 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance, ages 18-49, 50-64, 65 plus, year is between 2018 and 2022. Centers for Disease Control and Prevention. Last updated July 22, 2024. Accessed August 14, 2024. https://data.cdc.gov/Public-Health-Surveillance/1998-2022-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/data
- Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2018. Centers for Disease Control and Prevention. Updated May 22, 2020. Accessed June 14, 2024. https://stacks.cdc.gov/view/cdc/140450
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2019. Centers for Disease Control and Prevention. Updated June 16, 2021. Accessed January 14, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2020. Centers for Disease Control and Prevention. Updated September 20, 2022. Accessed October 15, 2024. https://stacks.cdc.gov/view/cdc/140328
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2021. Centers for Disease Control and Prevention. Updated June 2, 2023. Accessed January 14, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2022. Centers for Disease Control and Prevention. Updated July 5, 2024. Accessed September 4, 2024. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2022.pdf